Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08 Maio 2023 - 5:30PM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that, on
April 27, 2023, the Compensation Committee of Precision’s Board of
Directors approved the grant of inducement awards to new employees
under the Precision BioSciences, Inc. 2021 Employment Inducement
Incentive Award Plan (“Inducement Award Plan”). The inducement
awards consist of options to purchase (“stock options”) an
aggregate of 259,641 shares of Precision’s common stock, par value
$0.000005 (the “Common Stock”), which stock options were granted
among five employees in connection with their commencement of
employment. Each of the stock options were granted under Nasdaq
Listing Rule 5635(c)(4) as an inducement for the employees to
commence service with Precision.
The stock options have a per share exercise price equal to the
fair market value of Precision’s Common Stock on the grant date,
which was equal to $0.82. Each of the stock options has a 10-year
term and vests (subject to continued service to Precision through
the applicable vesting dates) as to 25% of the award on the first
anniversary of the date of the commencement of their employment
and, as to the remaining 75%, in substantially equal quarterly
installments over the three years thereafter.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple ex vivo clinical
candidates and several in vivo gene editing candidates designed to
cure genetic and infectious diseases where no adequate treatments
exist. For more information about Precision BioSciences, please
visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005495/en/
Mei Burris Director, Investor Relations and Finance
Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024